Disc Medicine (IRON) Non-Current Assets (2020 - 2026)
Disc Medicine (IRON) posted quarterly Non-Current Assets of $2.3 million for Q2 2026, down 33.41% year-over-year from $3.5 million in Q2 2025, and down 16.24% quarter-over-quarter from $2.8 million in Q1 2026.
Analysis
Disc Medicine (IRON) Non-Current Assets (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Non-Current Assets for 7 consecutive years, with $2.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Assets fell 33.41% year-over-year to $2.3 million; the TTM figure through Jun 2026 stood at $11.3 million (down 7.72% YoY), while the FY2025 annual figure was $3.0 million, down 5.6% from the prior year.
- Non-Current Assets retreated to $2.3 million in Q2 2026 per IRON's latest filing, from $2.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $3.7 million in Q1 2025 and bottomed at $204000.0 in Q2 2022.
- Historically, Non-Current Assets has averaged $2.2 million across 5 years, with a median of $2.3 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets plunged 81.64% — and 2023, when it soared 1096.57%.
- Disc Medicine's Non-Current Assets stood at $1.7 million in 2022, then jumped by 36.17% to $2.3 million in 2023, then surged by 35.3% to $3.2 million in 2024, then slipped by 5.6% to $3.0 million in 2025, then dropped by 22.51% to $2.3 million in 2026.
- Business Quant data shows IRON's Non-Current Assets at $2.3 million in Q2 2026, $2.8 million in Q1 2026, and $3.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Disc Medicine | 3.06 Bn | 3.06 Bn | - | 2.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.31 Mn |
| Mar 31, 2026 | 2.76 Mn |
| Dec 31, 2025 | 2.98 Mn |
| Sep 30, 2025 | 3.29 Mn |
| Jun 30, 2025 | 3.47 Mn |
| Mar 31, 2025 | 3.67 Mn |
| Dec 31, 2024 | 3.16 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | 2.23 Mn |
| Dec 31, 2023 | 2.33 Mn |
| Sep 30, 2023 | 2.23 Mn |
| Jun 30, 2023 | 2.44 Mn |
| Mar 31, 2023 | 1.64 Mn |
| Dec 31, 2022 | 1.71 Mn |
| Sep 30, 2022 | 1.37 Mn |
| Jun 30, 2022 | 204,000.00 |
| Mar 31, 2022 | 217,000.00 |
| Dec 31, 2021 | 1.93 Mn |
| Sep 30, 2021 | 735,000.00 |